CytoTools
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The last earnings update was 232 days ago. More info.
Add to Portfolio Compare Print
- CytoTools has significant price volatility in the past 3 months.
T5O Share Price and Events
7 Day Returns
1 Year Returns
T5O Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| CytoTools (T5O) | -7.4% | 33.4% | 88.4% | 61.2% | 6.4% | -77.1% |
| DE Biotechs | 0.3% | 1.9% | -1% | -8.3% | 58.9% | 13% |
| DE Market | -0.2% | -2.1% | 4.2% | -10.4% | 11.1% | 10.6% |
1 Year Return vs Industry and Market
- T5O outperformed the Biotechs industry which returned -8.3% over the past year.
- T5O outperformed the Market in Germany which returned -10.4% over the past year.
T5O Value
Is CytoTools undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
CytoTools
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for CytoTools.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 1 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.1% |
| Perpetual Growth Rate | 10-Year DE Government Bond Rate | 0.2% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year DE Govt Bond Rate | 0.2% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.38 (1 + (1- 30%) (10.07%)) |
1.32 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.32 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.32 * 5.96%) |
8.09% |
Discounted Cash Flow Calculation for XTRA:T5O using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for CytoTools is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (EUR, Millions) | Source |
Present Value Discounted (@ 8.09%) |
|
|---|---|---|---|
| 2019 | -8.90 | Analyst x1 | -8.23 |
| 2020 | -8.50 | Analyst x1 | -7.27 |
| 2021 | -9.50 | Analyst x1 | -7.52 |
| 2022 | 5.30 | Analyst x1 | 3.88 |
| 2023 | 21.90 | Analyst x1 | 14.84 |
| 2024 | 36.30 | Est @ 65.78% | 22.76 |
| 2025 | 53.05 | Est @ 46.11% | 30.77 |
| 2026 | 70.20 | Est @ 32.35% | 37.67 |
| 2027 | 86.15 | Est @ 22.71% | 42.76 |
| 2028 | 99.90 | Est @ 15.97% | 45.88 |
| Present value of next 10 years cash flows | €175.53 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= €99.90 × (1 + 0.23%) ÷ (8.09% – 0.23%) |
€1,273.18 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= €1,273.18 ÷ (1 + 8.09%)10 |
€584.70 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= €175.53 + €584.70 |
€760.23 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €760.23 / 2.12 |
€358.56 |
| Calculation | Result | |
|---|---|---|
| Value per share (EUR) | From above. | €358.56 |
| Current discount | Discount to share price of
€13.15
= -1 x (€13.15 - €358.56) / €358.56 |
96.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- CytoTools's share price is below the future cash flow value, and at a moderate discount (> 20%).
- CytoTools's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for CytoTools's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
CytoTools's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-06-30) in EUR | €-0.50 |
| XTRA:T5O Share Price ** | XTRA (2019-05-17) in EUR | €13.15 |
| Europe Biotechs Industry PE Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 22.59x |
| Germany Market PE Ratio | Median Figure of 426 Publicly-Listed Companies | 20.24x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of CytoTools.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = XTRA:T5O Share Price ÷ EPS (both in EUR) = 13.15 ÷ -0.50 |
-26.17x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CytoTools is loss making, we can't compare its value to the Europe Biotechs industry average.
- CytoTools is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does
CytoTools's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -26.17x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
Not available |
| Europe Biotechs Industry PEG Ratio | Median Figure of 22 Publicly-Listed Biotechs Companies | 1.3x |
| Germany Market PEG Ratio | Median Figure of 277 Publicly-Listed Companies | 1.51x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for CytoTools, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
CytoTools's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-06-30) in EUR | €4.97 |
| XTRA:T5O Share Price * | XTRA (2019-05-17) in EUR | €13.15 |
| Germany Biotechs Industry PB Ratio | Median Figure of 14 Publicly-Listed Biotechs Companies | 3.35x |
| Germany Market PB Ratio | Median Figure of 576 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = XTRA:T5O Share Price ÷ Book Value per Share (both in EUR) = 13.15 ÷ 4.97 |
2.64x |
* Primary Listing of CytoTools.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CytoTools is good value based on assets compared to the DE Biotechs industry average.
Value checks
We assess CytoTools's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) CytoTools has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
T5O Future Performance
How is CytoTools expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare CytoTools's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare CytoTools's earnings growth to the Germany market average as no estimate data is available.
- CytoTools's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| XTRA:T5O Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts | 66.9% |
| Germany Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 52.3% |
| Germany Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 32.6% |
| Germany Market Earnings Growth Rate | Market Cap Weighted Average | 13.1% |
| Germany Market Revenue Growth Rate | Market Cap Weighted Average | 4.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (10 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 100 | 23 | 1 | |
| 2022-12-31 | 44 | 5 | 1 | |
| 2021-12-31 | 11 | -9 | 1 | |
| 2020-12-31 | 5 | -8 | 1 | |
| 2019-12-31 | 1 | -9 | 1 | |
| 2018-12-31 | 0 | -5 | 1 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-06-30 | 0 | -1 | -1 |
| 2018-03-31 | 0 | -1 | -1 |
| 2017-12-31 | 0 | -1 | -1 |
| 2017-09-30 | 0 | -1 | -1 |
| 2017-06-30 | -1 | -1 | |
| 2017-03-31 | -1 | -1 | |
| 2016-12-31 | -1 | -1 | |
| 2016-09-30 | -1 | -1 | |
| 2016-06-30 | -1 | -1 | |
| 2016-03-31 | -1 | -1 | |
| 2015-12-31 | -1 | -1 | |
| 2015-09-30 | 0 | -2 | -1 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (10 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from CytoTools Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | ||||
| 2021-12-31 | ||||
| 2020-12-31 | ||||
| 2019-12-31 | ||||
| 2018-12-31 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | -0.50 |
| 2017-09-30 | -0.50 |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | -0.49 |
| 2016-09-30 | -0.54 |
| 2016-06-30 | |
| 2016-03-31 | |
| 2015-12-31 | -0.66 |
| 2015-09-30 | -0.67 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if CytoTools will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess CytoTools's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
CytoTools has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
T5O Past Performance
How has CytoTools performed over the past 5 years?
- CytoTools's last earnings update was 232 days ago.
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- CytoTools does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare CytoTools's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare CytoTools's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from CytoTools Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-06-30 | 0.09 | -1.15 | 0.31 | |
| 2018-03-31 | 0.09 | -1.11 | 0.32 | |
| 2017-12-31 | 0.09 | -1.07 | 0.33 | |
| 2017-09-30 | 0.04 | -1.06 | 0.33 | |
| 2017-06-30 | -1.06 | 0.34 | ||
| 2017-03-31 | -1.02 | 0.33 | ||
| 2016-12-31 | -0.98 | 0.32 | ||
| 2016-09-30 | -1.09 | 0.36 | ||
| 2016-06-30 | -1.20 | 0.40 | ||
| 2016-03-31 | -1.25 | 0.42 | ||
| 2015-12-31 | -1.30 | 0.44 | ||
| 2015-09-30 | 0.00 | -1.34 | 0.38 | |
| 2015-06-30 | 0.00 | -1.37 | 0.32 | |
| 2015-03-31 | 0.15 | -1.20 | 0.32 | |
| 2014-12-31 | 0.30 | -1.04 | 0.32 | |
| 2014-09-30 | 0.31 | -0.91 | 0.40 | |
| 2014-06-30 | 0.33 | -0.79 | 0.48 | |
| 2014-03-31 | 0.19 | -0.96 | 0.51 | |
| 2013-12-31 | 0.05 | -1.14 | 0.54 | |
| 2013-09-30 | 0.05 | -1.03 | 0.47 | |
| 2013-06-30 | 0.05 | -0.92 | 0.41 | |
| 2013-03-31 | 0.05 | -0.79 | 0.36 | |
| 2012-12-31 | 0.05 | -0.66 | 0.31 | |
| 2012-09-30 | 0.05 | -0.71 | 0.30 | |
| 2012-06-30 | 0.05 | -0.77 | 0.29 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if CytoTools has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if CytoTools has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if CytoTools improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess CytoTools's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
CytoTools has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
T5O Health
How is CytoTools's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up CytoTools's finances.
The net worth of a company is the difference between its assets and liabilities.
- CytoTools's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- CytoTools's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from CytoTools Company Filings, last reported 10 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-06-30 | 10.92 | 2.81 | 1.64 |
| 2018-03-31 | 10.92 | 2.81 | 1.64 |
| 2017-12-31 | 10.54 | 0.10 | 2.06 |
| 2017-09-30 | 10.54 | 0.10 | 2.06 |
| 2017-06-30 | 10.88 | 0.00 | 2.06 |
| 2017-03-31 | 10.88 | 0.00 | 2.06 |
| 2016-12-31 | 10.01 | 0.00 | 1.42 |
| 2016-09-30 | 10.01 | 0.00 | 1.42 |
| 2016-06-30 | 10.42 | 0.00 | 1.87 |
| 2016-03-31 | 10.42 | 0.00 | 1.87 |
| 2015-12-31 | 10.87 | 0.00 | 3.28 |
| 2015-09-30 | 10.87 | 0.00 | 3.28 |
| 2015-06-30 | 8.06 | 0.00 | 0.50 |
| 2015-03-31 | 8.06 | 0.00 | 0.50 |
| 2014-12-31 | 8.52 | 0.00 | 0.73 |
| 2014-09-30 | 8.52 | 0.00 | 0.73 |
| 2014-06-30 | 8.15 | 0.00 | 0.43 |
| 2014-03-31 | 8.15 | 0.00 | 0.43 |
| 2013-12-31 | 8.10 | 0.00 | 1.82 |
| 2013-09-30 | 8.10 | 0.00 | 1.82 |
| 2013-06-30 | 8.74 | 0.00 | 3.89 |
| 2013-03-31 | 8.74 | 0.00 | 3.89 |
| 2012-12-31 | 6.20 | 0.00 | 1.30 |
| 2012-09-30 | 6.20 | 0.00 | 1.30 |
| 2012-06-30 | 6.03 | 0.00 | 2.03 |
- CytoTools's level of debt (25.7%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 25.7% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- CytoTools has sufficient cash runway for 1.2 years based on current free cash flow.
- CytoTools has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -26.6% each year.
Financial health checks
We assess CytoTools's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) CytoTools has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
T5O Dividends
What is CytoTools's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
CytoTools
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate CytoTools's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate CytoTools's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| Germany Market Average Dividend Yield | Market Cap Weighted Average of 327 Stocks | 3.1% |
| Germany Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| Germany Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| Germany Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 | ||
| 2018-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as CytoTools has not reported any payouts.
- Unable to verify if CytoTools's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess CytoTools's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can CytoTools afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) CytoTools has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
T5O Management
CEO
| TENURE AS CEO | 19.3 years |
CEO Bio
Dr. Mark-André Freyberg co-founded CytoTools AG in 2000 and serves as Chief Executive Officer and Chairman of Management Board also served as its Managing Director. Dr. Freyberg served as the Head of Project, Cell Culture Technology at the Institute for Biochemistry at Darmstadt Technical University. In, 2000, he became a Co-Founder and Chief Executive Officer of CytoTools AG. There, he coordinated research activities and was responsible for the successful first round financing. Furthermore, support was obtained from BioChance, the largest German biotechnology funding program from the German Federal Ministry for Education and Research. Under Dr. Freyberg's leadership, the results of the basic research reached the stage of proof of conception in three animal models. Parallel to this, working was extended to the indications wound healing and dermatology. The medical successes led to the foundation of DermaTools Biotech GmbH in 2004 and TemplaTech GmbH in 2005 where he is also Chief Executive Officer. He has special responsibility for the fields of marketing of active substances and financing at CytoTools AG. After completing his diploma studies in biology, focusing on microbiology, in 1995 , Dr. Freyberg completed a doctorate in the fields of biochemistry and biotechnology at Darmstadt Technical University. Concomitantly with his dissertation, he additionally studied business science at the Hagen Distance Learning University.
CEO Compensation
- Insufficient data for Mark-André to compare compensation growth.
- Insufficient data for Mark-André to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team
Mark-André Freyberg
Chairman of Management Board & CEO
19.3 yrs
Peter Friedl
Vice-Chairman of Management Board
Dirk Kaiser
Co-Founder & Member of Management Board
Board of Directors
Manfred May
Chairman of Supervisory Board
Herr Hoffmann
Member of Supervisory Board
Rüdiger Weseloh
Member of Supervisory Board
Jutta Schnirring-Mayer
Member of Supervisory Board
2.8 yrs
Heiner Hoppmann
Member of Supervisory Board
60
1.8 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess CytoTools's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) CytoTools has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
T5O News
Simply Wall St News
Who Are CytoTools AG's (ETR:T5O) Major Shareholders?
View our latest analysis for CytoTools XTRA:T5O Ownership_summary Mar 23rd 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions.
Simply Wall St - – Full articleDoes CytoTools AG's (ETR:T5O) Earnings Growth Make It An Outperformer?
When CytoTools AG (XTRA:T5O) announced its most recent earnings (30 June 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Viewing growth from a sector-level, the DE biotechs industry has been growing its average earnings by double-digit 21.32% over the past year, and 19.21% over the past half a decade.
Simply Wall St - – Full articleT5O Company Info
Description
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.
Details
| Name: | CytoTools AG |
| T5O | |
| Exchange: | XTRA |
| Founded: | 2000 |
| €27,881,313 | |
| 2,120,252 | |
| Website: | http://cytotools.de |
| Address: |
CytoTools AG Klappacher Strasse 126, Darmstadt, Hessen, 64285, Germany |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| XTRA | T5O | Bearer Shares | XETRA Trading Platform | DE | EUR | 13. Dec 2006 | |
| OTCPK | CYTT.F | Bearer Shares | Pink Sheets LLC | US | USD | 13. Dec 2006 | |
| DB | T5O | Bearer Shares | Deutsche Boerse AG | DE | EUR | 13. Dec 2006 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/18 21:15 |
| End of day share price update: | 2019/05/17 00:00 |
| Last estimates confirmation: | 2019/03/18 |
| Last earnings filing: | 2018/09/28 |
| Last earnings reported: | 2018/06/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
